AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Advanced Stent Technologies Announces Jerry Caulder as New Chairman and CEO And Jay Brumfield as President and COO.
PLEASANTON, Calif., Aug. 29 /PRNewswire/ -- Advanced Stent Technologies, Inc. (AST), a medical device company, today announced the appointment of Jerry Caulder, Ph.D., as Chairman and Chief Executive Officer and Jay Brumfield as President and Chief Operating Officer.
Dr. Caulder has extensive experience in executive management and in developing strong operational teams and strategic plans for small technology startups. He started his professional career with Monsanto Company in 1969 where he held various positions until 1984. Between 1984-1998, he served as the President and Chief Executive Officer of Mycogen Corporation until it was sold to Dow Chemical Company. In 1998, Dr. Caulder became Executive Chairman and Chief Executive Officer of Myelos Neuroscience. He served Myelos until it was sold to Biotechnology General Corp. He is currently a member of several Board of Directors and advisory boards, including for Athenix Corp, New Zealand's AgResearch and the Burrill Venture Capital Group.
Dr. Caulder is the former Chairman of the Industrial Biotechnology Association, a predecessor to the Biotechnology Industry Organization (BIO) and has served on BIO's Board of Directors and chaired its Food and Agriculture Section. He has served on and chaired several committees of the U.S. Office of Technology Assessment and advised foreign governments on agriculture and biotechnology. He has been a consultant and speaker to numerous organizations, including the Brookings Institute, The Keystone Group and the World Economic Forum. He has been profiled in Forbes and USA Today and is frequently quoted in the national media.
Dr. Caulder earned his B.S. degree in Biology from Southeast Missouri State University and an M.S. and Ph.D. in Plant Physiology and Agronomy from the University of Missouri at Columbia.
"AST's prospects for building on its leadership role in the development of coronary bifurcation solutions are compelling. I am very excited to become a part of AST," stated Dr. Caulder.
Jay Brumfield, who will ...
- Advanced Stent Technologies, Inc. Receives CE Mark Approval for SLK-View(TM)...
- Press release article from: PR Newswire February 4, 2003 700+ words
...PRNewswire/ -- Advanced Stent Technologies, Inc. (AST) announced...Chief Operating Officer and Vice President, Research and Development...About AST Advanced Stent Technologies, Inc., incorporated...President, Advanced Stent Technologies, Inc.,
- Advanced Stent Technologies, Inc. Announces Changes in Management, New...
- Press release article from: PR Newswire May 14, 2002 700+ words
...Calif. -- Advanced Stent Technologies, Inc. (AST...Officer; Ilana Odess, Vice President, Marketing and Sales; Michal Geva, Vice President, Regulatory Affairs...joined AST as Executive Vice President - Corporate Affairs...
- Advanced Stent Technologies restructures managment.
- Newspaper article from: Health & Medicine Week June 17, 2002 700+ words
...amp; NewsRx.net) -- Advanced Stent Technologies, Inc., (AST) a development stage...technology officer; Ilana Odess, vice president, marketing and sales; Michal Geva, vice president, regulatory affairs, clinical affairs...
- Advanced Stent Technologies, Inc. Receives FDA Approval to Commence Feasibility...
- Press release article from: PR Newswire November 14, 2001 700+ words
...PLEASANTON, Calif., Nov. 14 /PRNewswire/ -- Advanced Stent Technologies, Inc. (AST), a development stage company that is developing...Sepehr Fariabi, PhD, AST's Chief Operating Officer and Vice President of Research and Development, "Our SLK-View(TM) stent...
- Pre-clinical Data Show OrbusNeich's Combo Bio-engineered Sirolimus Eluting...
- Press release article from: PR Newswire September 23, 2009 700+ words
...sirolimus sustained drug elution for the control of neointimal proliferation. Stephen M. Rowland, Ph.D., OrbusNeich's vice president of research and development, said, "Combo will enable us to expand on the benefits offered by our Genous technology...
- Advanced Stent Technologies, Inc./.
- Press release article from: PR Newswire November 18, 2001 700+ words
...news release, Advanced Stent Technologies, Inc. Announces Establishment...Nov. 14, by Advanced Stent Technologies, Inc. over PR Newswire...release follows: Advanced Stent Technologies, Inc. Announces Establishment...
- Advanced Stent Technologies, Inc. Chairman/Chief Medical Officer Dr. Gil Vardi...
- Press release article from: PR Newswire April 23, 2003 700+ words
...interventional cardiologist, and Advanced Stent Technologies, Inc. jointly announced today that...to work full-time for Advanced Stent Technologies, Inc. "AST's tremendous advances...delivery systems." About AST Advanced Stent Technologies, Inc., incorporated in 1998...
- Advanced Stent Technologies, Inc. Announces Commencement Of U.S. Pivotal Study...
- Press release article from: PR Newswire April 7, 2003 700+ words
...April 7 /PRNewswire/ -- Advanced Stent Technologies, Inc. (AST) announced today that...FDA approval. About AST Advanced Stent Technologies, Inc., incorporated in 1998...E. Weber, President of Advanced Stent Technologies, Inc., +1-925-931-2721...